Abstract: PURPOSE OF REVIEW: Rheumatoid arthritis (RA) is a systemic, autoimmune disease resulting in the destruction of affected joints. Even though current therapies with biologics such as tumor necrosis factor-alpha blockers yield significant improvement for the patients, the disease is not curable yet. Therefore, we need novel strategies for better therapies. RECENT FINDINGS: The growing knowledge of epigenetics might give us new insights into the pathogenesis of autoimmune diseases. In the last year, several new findings about epigenetic modifications of gene expression were reported in different arthritides. These modifications describe changes in the expression of DNA that result from methylation, posttranslational modifications of the histone proteins, including acetylation/deacetylation, sumoylation, methylation and microRNAs. Most interestingly, these modifications seem to act in concert and are associated with the circadian metabolic rhythm of cells. SUMMARY: This review summarizes reports from the last year about epigenetic modifications of gene expression via acetylation/deacetylation, including sirtuins, sumoylation, methylation, microRNAs in all in rheumatoid arthritis and other arthritides, providing potential strategies for better therapies and encourages the development of specific epigenetic drugs. 
Introduction:
We summarize here reports from the last year about epigenetic modifications that control the regulation of gene expression in autoimmune diseases. Epigenetic modifications of synovial cells such as fibroblasts, chondroyctes and endothelial cells and also from PBMCs were reported in different arthritides. This knowledge gives us novel insights into the pathogenesis of these diseases and allows in future the development of more specific epigenetic drugs.
Text of review:

HDACs and sirtuins
Protein acetylation is the best described posttranslational modification of histones that is able to regulate the transcription of genes. Acetylation of histones is mediated These results help us to understand how chromatin remodeling enzymes work in the transcriptional regulation. However, the specific repression of genes by HDAC isoforms, their binding sites on DNA and interactions with other DNA binding molecules is not known yet.
HDACs have been reported to be included in many cellular pathways and their dysreguation has been linked to multiple cancers as well as to autoimmune diseases (8) (9) (10) (11) (12) . Our group reported a reduction of total HDAC activity in the synovial tissue of patients with RA and a significant downregulation of the isoform proteins HDAC1 and HDAC2 suggesting that HDACs are intrinsically reduced and therefore might not be suitable for further treatment by HDAC inhibitors (HDACi) (13) . However, in several animal studies HDACi showed beneficial effects for treatment of arthritis (14) (15) (16) .
These results show that further knowledge of HDACi on histones and non-histone proteins in different cell populations is necessary before these drugs can be safely used for the treatment of RA (Table 1) .
To understand the function of acetylases/deacetylases in regard to the production of matrix metalloproteinases (MMPs) we established their expression pattern in the synovial fibroblasts (RASF) which are the effector cells leading to cartilage destruction in RA (17) . In contrast to synovial tissues, we could not detect a decreased expression of HDAC1 and 2 in TNF- and IL-1β stimulated RA synovial fibroblasts, and therefore these HDACs do not contribute to the increased activity of acetylation seen in the tissue. But, stimulation of the RASF with TNF- and IL-1β to mimic the inflammatory milieu in the affects joints resulted in an increase of the global acetylation status of the cells and reduced expression of the isoforms HDAC 3, 4 and 7 (18) . Treatment of the cells with the HDACi trichostatin A resulted in a significant downregulation of HDAC7 (19) . In addition, TSA also downregulated the expression A misregulation of HDAC isoforms was also reported in other arthritides.
Overexpression of HDAC1 and 2 proteins was demonstrated in human chondrocytes from OA cartilage consistent with a downregulation of cartilage marker genes.
Overexpression of these HDACs repressed specific cartilage marker genes such as aggrecan and collagen 2 and to a different extent also collagen 9, collagen 11, dermatopontin and cartilage oligomeric protein (COMP) whereas silencing of HDAC1 and 2 by siRNA or HDACi increased cartilage gene expression. Removal or exchange of one of the DNA binding sites, the carboxy-terminal domain (CTDs), showed altered target gene repression specificity for HDAC1 and HDAC2. The most interesting point of this study is that these CTDs can function independently of the HDAC enzymatic activity to target HDACs to specific genes (22) . Others reported elevated levels of the isoform, HDAC7 in OA cartilage compared to healthy donors.
Silencing of HDAC7 in a human chondrosarcome cell line suppressed the IL-1 induced expression of MMP13 suggesting that specific HDAC7 suppression may prevent the increased matrix degradation in OA (23) .
In another study, HDAC inhibitors were shown to antagonize FGF2 and IL-1 induced expression of MMP1, 3 and 13 in cultured human articular chondrocytes, also suggesting HDAC inhibition as intervention in OA. But further analysis showed that also cartilage matrix proteins such as COL2A1 and aggrecan were also reduced by the treatment with TSA. Whether HDACi may slow down cartilage turnover and thereby inhibit the progression of cartilage destruction to preserve existing cartilage needs to be evaluated in animal models (24) .
Together, the mentioned studies suggest that HDACs might have several functions and targets, namely the deacetylase activity on histone proteins and non-histone proteins and repression of gene expression by binding to promoter regions alone or in complex with other DNA binding molecules. Therefore, it is very important to explore all the possible effects of HDAC isoforms before using them for treatment. blocked angiogenesis (25) . The function of HDAC7 in endothelial cells has been attributed to the repression of the transcription factor MEF2 resulting in the inhibition of MMP-10 (26) whereas the proangiogenic function of HDAC9 was not described before. Of interest is that the repressive function of HDAC5 was independent of the direct deacetylase activity of HDAC5 suggesting an interaction with other DNA binding molecules or other HDAC isoforms as it is described for class II HDACs.
However, the deacetylase-deficient HDAC5 mutant which lacks also the C-terminus still repressed endothelial function, implying other mechanism for the antiangiogenic effects. The authors suggest that the N-terminal part of HDAC5 might also repress transcriptional activity through interaction with co-repressors such as HP1 or CtBP.
In RA HDAC inhibitors were also used to alter gene expression in hematopoietic cells. In RA, regulatory T cell function is defective because they are unable to prevent the release of inflammatory cytokines from effector CD4 Most interestingly, the circadian regulator CLOCK is a histone acetyltransferase which is counterbalanced by the deacetylase activity of SIRT1. In vivo CLOCK acetylates and activates its partner BMAL1. Both together induce the circadian expression of nicotinamide phosphoribosyltransferase (NAMPT) by binding to its Eboxes in the promoter. Nampt on the other site provides the important cofactor NAD+ for the counter player SIRT1. For the deacetylation activity, SIRT1 is also recruited to the NAMPT promoter and contributes to its repression and therefore to the the circadian synthesis of its own coenzyme. The NAMPT inhibitor FK866 significantly lowered cellular NAD+ and NAM levels and increased acetylation of the CLOCK partner BMAL1 similar to the effect of inhibition of SIRT1 (44, 45) . Nampt, also known as PBEF (Pre-B-cell colony-enhancing factor) or visfatin, is upregulated in the synovial tissues from patients with RA and induced by toll-like receptors signaling in isolated synovial fibroblasts (RASF) (46) .
Since calorie restriction decreases NADH levels, changes in the intracellular NAD+/NADH ratios have also impact on sirtuin deacetylase activity in the cells. In addition, metabolic stress such as prolonged fasting is known to activate Nampt which regulates SIRT1-dependent activities by its capacity to provide the SIRTcofactor NAD (38, 47) . Our group reported Nampt/PBEF not only as a novel marker of inflammation in RA with proinflammatory but also matrix-degrading activities (46) . Sumoylation is one of the modulators of sirtuin activity. SIRT1 can be modified at Lys-734 by the addition of a SUMO-group which increases the SIRT1 deacetylation activity (54) . In contrast, the recruitment of the SUMOylase SENP-1 resulted in desumoylation and therefore repression of SIRT1 deacetylase activity and consequently acetylation and activation of target proteins such as p53. We reported an intrinsic upregulation of SUMO in synovial fibroblasts from patients with RA leading to their increased resistance of apoptosis by SUMOylation of promyelocytic leukemia protein (PML) and recruitment of DAXX to PML nuclear bodies (NBs) (55, 56) . In contrast, the induced upregulation of the SUMO-protease SENP-1 which is normally downregulated in RASF was able to reverse this effect. Since SIRT-1 is also recruited to the PML NBs in the cells, and binds and regulate p53 expression an increased SUMOylation of SIRT1 might contribute to the apoptosis resistance of RASF (57) . Whether SIRT1 itself is activated by hypoxia is not clear yet. But the SIRT1/HIF2a complex formation as well as SIRT1 mediated deacetylation of acetylated HIF2a during hypoxia or other environmental stress offers novel therapeutic opportunities also for RA (63, 64) .
The function of SIRT1 in the endothelium was revealed by an impaired ability of SIRT 1 mutant mice to form new vessels in response to angiogenic signals (65, 66) .
Although endothelial cells express all sirtuins (1 to 7), knock down of SIRT1 was associated with a loss of sprouting angiogenesis in vitro. Since RA is characterized by inflammation and endothelial dysfunction (67) these results suggest that SIRT1 is a novel modulator of normal endothelial function and that overexpression of SIRT1 might be vasoprotective (68) .
However, we have only limited knowledge about the mechanisms that regulates the function of SIRT1. Recently, miRNA 217 was observed to be overexpressed during endothelial senescence whereas SIRT1 levels decreased at the same time. 
Methylation
Methylation is the best analyzed posttranslational modification regulating gene expression and contributing to several diseases, in particular autoimmune diseases (72, 73) . Recently, we demonstrated that the DNA in RA synovial fibroblasts is hypomethylated, resulting in the activated and aggressive phenotype of these cells (74). Our group showed also that proliferating RASFs are deficient in DNA methyltransferase 1 (DNMT1) compared to OASF and the DNA showed fewer 5-methylcytosine and methylated CG marks upstream of an L1 open-reading frame.
Moreover, using 5-azacytydine, a potent inhibitor for DNMT1, on healthy fibroblasts the activated phenotype could be induced by upregulation of genes, including growth factors and receptors, extracellular matrix proteins, adhesion molecules, and matrixdegrading enzymes. These data suggest that DNA hypomethylation contributes to the chronicity of RA and could be responsible for the limitation of current therapies (75) . 
Conclusion:
In summary, the reported data clearly demonstrate that the epigenetic modulations observed in health and disease are regulated by novel mechanisms including acetylation, methylation, sumoylation and microRNA. In this regard a complete new class of drugs is evolving (6) .
